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The redox-active chlorite-based drug WF10 (Immunokine) was shown to have modulatory eﬀects on both the innate and
adaptive immune system in vitro and in vivo. Animal studies suggest that WF10 enhances immunity against tumors. One possible
explanation for such an eﬀect is that WF10 stimulates natural killer cell cytotoxicity against malignant cells. Here, we show that
WF10regulates humanNK cell cytotoxicity in a time-dependent manner,followingan S-shaped kineticwith an initialstimulation
of activity followed by a decrease in activity relative to the untreated controls. WF10 does not activate NK cells on its own but co-
stimulates NK cell activation mediated by diﬀerent activating receptors. This is mediated by enhancing NK cell adhesion to target
cells through promoting the activation of the integrin LFA-1. These data demonstrate a direct eﬀect of WF10 on the cytotoxicity
of human NK cells.
1.Introduction
Natural killer (NK) cells are important eﬀector cells for
innate immune reactions against viral infections and malig-
nant cells [1]. NK cell eﬀector functions include cellular
cytotoxicity and the secretion of cytokines and chemokines.
They also fulﬁll a regulatory role by engaging in cross-talk
with diverse cellular components of the immune system [2].
NK cell cytotoxicity is regulated through the recognition
of target cells by integrating positive and negative signals
from activating and inhibitory receptor-ligand interactions
[3]. Many inhibitory NK cell receptors are speciﬁc for self-
MHC class I and are important to ensure the self-tolerance
of NK cells. Loss of MHC class I upon viral infection or
malignant transformation can, therefore, result in the so-
called“missing-self” reactivity ofNKcells. NKcellactivation
is mediated by a variety of diﬀerent surface receptors that
can recognize speciﬁc ligands on transformed or infected
cells. Interestingly, freshly isolated resting human NK cells
can only be activated by triggering two or more activating
receptors in combination [4]. Therefore, all stimulatory
receptors for natural cytotoxicity are considered to be
coactivating. The only exception seems to be CD16, which
is suﬃcient by itself to induce activation of resting NK cells.
NK cell adhesion to target cells is essential for enabling
the interaction between NK cell receptors and their ligands
within the immunological synapse and for the directed
release of granules towards the attached target cell during
NK cell cytotoxicity [5]. NK cell adhesion is mediated
by integrins such as LFA-1. The function of LFA-1 is
regulated by “inside-out signaling”, where signals from other
surface receptors inﬂuences the aﬃnity of LFA-1 by inducing
conformational changes of the molecule, and also aﬀects
the avidity of LFA-1 by driving mobility within the cell
membrane [6]. This results in clustering of LFA-1 at the
site of the NK cell synapse. Adhesion is, therefore, a highly
regulated and dynamic process necessary for the function of
NK cells.2 Journal of Biomedicine and Biotechnology
WF10, or Immunokine, is based on the chlorite ion
matrix tetrachlorodecaoxygen and is currently being eval-
uated in various clinical indications including the adju-
vant therapy of inoperable pancreatic cancer and various
inﬂammatory conditions [7–9]. WF10 is known to have
variousimmunologicaleﬀectsbystimulatinginnateimmune
functions, while inhibiting adaptive immune functions [10].
In contrast to control animals, sublethally irradiated rats
treated with WF10developedsigniﬁcantly less hematological
or solid tumors than controls [11, 12]. This antitumor eﬀect
ofWF10couldbeexplainedbystimulatingtheinnatenatural
cytotoxicity against tumors. We, therefore, investigate the
eﬀect of WF10 on NK cell cytotoxicity.
2.Materialsand Methods
2.1. Materials and Cells. WF10/Immunokine (containing
ca. 63μM chlorite) was provided by Dimethaid GmbH,
Wanzleben, Germany. The following antibodies were used:
MOPC21 (IgG1 isotype control, Sigma), antiNKp30 (p30-
15, generated in our lab), antiNKp46 and antiCD16
(Beckmann Coulter), anti2B4 (Immunotech), antiNKG2D
and antiDNAM-1 (R&D Systems). Human ICAM-1-Fc
was from R&D Systems, PE-conjugated goat-antihuman
Fcγ fragment-speciﬁc IgG F(ab
 )2 fragment from Jackson
Immuno Research. K562, LCL721.221 and P815 cells were
maintained as described [13, 14]. Human NK cells were iso-
lated from PBMC by negative selection (Dynal, Invitrogen)
and cultured as described [15].
2.2. Cytotoxicity Assay. For 51Cr release assays, target cells
were labeled with 100μCi of 51Cr for 1h at 37◦C. The labeled
cells were washed, mixed with NK cells at diﬀerent eﬀector-
to-target (E:T) ratios on a 96-well V-bottom plate and
incubated for 4h at 37◦C. For redirected lysis assay NK cells
were preincubated with antibodies (0.5μg/ml ﬁnal concen-
tration)for 15min at37◦Cbeforeaddingthetargetcells. The
supernatant was harvested and 51Cr-release was measured in
aγ-counter.Percentspeciﬁcreleasewascalculatedas((exper-
imental release-spontaneous release)/(maximum release-
spontaneous release)) × 100. The ratio between maximum
and spontaneous release was at least three in all experiments.
2.3. Real-Time PCR Analysis. NK cells were incubated with
or without WF10 for 3 or 18h. At the end of the incubation
cells were lysed in 300μl MagNA pure lysis buﬀer containing
1% DTT and mRNA was isolated using the MagnaPure-LC
device. Isolated mRNA was transcribed into cDNA using
AMV reverse transcriptase (First Strand cDNA synthesis
kit (Roche)). Indicated primer sets (Search-LC, Heidelberg)
were used with LightCycler-FastStart DNS Sybr Green I Kit
(Roche) to amplify the cDNA using the LightCycler accord-
ing to the manufacture’s protocol.The number oftranscripts
of speciﬁc genes in each sample was normalised using the
number of transcripts of the house-keeping genes β-actin
and cyclophilin b. The transcript number was calculated
from a virtual standard curve, obtained by plotting a known
input concentration of a plasmid to the PCR cycle number
(CP) at which the detected ﬂuorescence intensity reaches a
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Figure 1:Eﬀect ofWF10 onthe cytotoxic activity ofNKcells. (a, b)
Freshly isolated resting human NK cells or (c, d) IL-2 stimulated
NK cells were used in a standard 4h 51Cr-release assays against
LCL721.221 target cells with or without the addition of 200μM
WF10 at the indicated eﬀector to target (E/T) ratios. Panels (a) and
(c) showthe results of representative experiments. In panels(b) and
(d) the activity of the WF10-treated cells is shown relative to the
cytotoxic activity of control cells (set as 100%) as an average value
from (b) 24 or (d) 3 independent experiments. The ratio of each
outcome and its control was tested againsta value of1 (equality) by
two-sided single-sample t-tests (∗P<. 05).
ﬁxed value. For better visualization, a log2 transformation,
of the ratio between WF10-treated and control samples was
calculated, as is common for gene expression studies [10].
2.4. Conjugate Formation Assay and Ligand Complex-Based
Adhesion Assay (LC-AA). NK cell-target cell conjugate for-
mation was measured by ﬂow cytometry as described
previously [13]. Brieﬂy, freshly isolated NK cells were labeled
withthedyePKH67andLCL721.221targetcellswithPKH26
(Sigma). Target and NK cells were combined and incubated
with or without WF10 (ﬁnal concentration of 200μM
chlorite) at 37◦C. Reactions were stopped by vortexing, cells
were ﬁxed with ice-cold 4% PFA and number of conjugates
were determined by FACS analysis. The ligand-complex-
based adhesion assay (LC-AA) assesses the activation of
the adhesion molecule LFA-1 by FACS analysis of cell
bound ﬂuorescently-labeled ICAM-1-complexes and was
performed as published [16, 17]. For statistical analysis SPSS
Statistics 17.0 was used.Journal of Biomedicine and Biotechnology 3
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Figure 2: WF10 speciﬁcally aﬀects NK cells. (a) Freshly isolated
resting human NK cells were preincubated for 5h with or without
200μM WF10 in culture medium, washed and then used in a
standard 4h 51Cr-release assays against LCL721.221 target cells at
the indicated eﬀector to target (E/T) ratios. (b) LCL721.221 target
cells were preincubated with or without 200μMW F 1 0i nc u l t u r e
medium, washed and then used as targets in a standard 4h 51Cr-
releaseassaysusingfreshlyisolatedhumanNKcells aseﬀectors. The
activity of the WF10-treated cells is shown relative to the cytotoxic
activity of control cells (set as 100%) as an average value from (a) 4
or (b) 3 independent experiments.
3.Resultsand Discussion
3.1. WF10 Can Increase the Cytotoxic Activity of Human NK
Cells. To test whether WF10 is able to boost the cytotoxic
activity of NK cells, we used freshly isolated human NK cells
in a standard 4h 51Cr-release assay against the MHC class
I-negative B cell line LCL721.221. At a therapeutic concen-
tration of 200μM active chlorite content WF10 signiﬁcantly
enhanced the cytotoxic activity of NK cells (Figures 1(a) and
1(b)).ThiseﬀectwasalsoseenwhenPBMC(datanotshown)
and IL-2-activated human NK cells were used (Figures 1(c)
and 1(d)). The enhancement of the NK cell cytotoxicity
by WF10 was dose-dependent and could also be observed
when NK cells were pretreated with WF10 before the assay
(Figure 2(a)). However, WF10 did not directly aﬀect the
viability of target cells and pretreatment of target cells with
WF10 did not alter their susceptibility to NK-mediated lysis
(Figure 2(b)). These datademonstrate thatWF10 speciﬁcally
enhances the cytotoxic activity of NK cells. This eﬀect was
not restricted to 721.221 target cells, but also the lysis of the
leukemic cell line K562 and the pancreatic cancer cell line
Miapaca were enhanced by WF10 (data not shown).
3.2. Time-Dependent Eﬀect of WF10. The increase in NK cell
cytotoxicity by WF10 was time-dependent, following an S-
shaped kinetic over 24hours (Figure 3).Afteran initial boost
of activity, WF10 inhibited NK cell cytotoxicity after 18h
of pretreatment (Figures 3(b) and 3(c)). Preincubation of
NK cells for 24 hours did no longer result in diﬀerences of
cytotoxicitybetween WF10 orcontrol treated cells. The inhi-
bitionofNKcellcytotoxicitywasnotduetoacytotoxiceﬀect
of WF10 as we only detected a minor increase in NK cell
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Figure 3: Time-dependent modulation of NK cell responses
by WF10. (a) Freshly isolated resting human NK cells or were
preincubated for the indicated times with 200μMW F 1 0a n dt h e n
used in a standard 4h 51Cr-release assays against LCL721.221
target cells. Cytotoxic activity was normalized to the untreated
control (set as 100%). Shown are the average values of two
independent experiments using NK cells from diﬀerent donors. (b,
c) Freshly isolated resting human NK cells were incubated with or
without 200μM WF10 in culture medium for 18h. Cells were then
resuspended in fresh medium and tested as described above. Panel
(b) showstheresults ofa representative experiment. Inpanel (c) the
activity of the WF10-treated cells is shown relative to the cytotoxic
activity of control cells (set as 100%) as an average value from 8
independent experiments. Theratioofeachoutcomeanditscontrol
wastested againsta value of 1 (equality) by two-sided single-sample
t-tests (∗P<. 05).
apoptosis after 18h of WF10-treatment. However, consistent
with previous ﬁndings that WF10 aﬀects gene transcription
by modulating certain transcription factors in PBMC [10],
we detected a reduced expression of cytotoxicity-related
genes such as NKG2D, Perforin and DAP12 by quantitative
RT-PCR after 18h of WF10-treatment (Figure 4), which
might explain the reduction in cytotoxicity.
3.3. WF10 Enhances NK Cell Cytotoxicity Mediated by
Diﬀerent Activating Receptors. Next we wanted to test if
the WF10-mediated enhancement of NK cell activity was
mediated through a speciﬁc activating receptor. Therefore,
we triggered NK cell cytotoxicity through NKp30, NKG2D
or 2B4 in a redirected lysis assay. In line with the concept
of NK cell coactivation [4], triggering of any of these4 Journal of Biomedicine and Biotechnology
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Figure 4: The eﬀect of WF10 on the transcription of NK cell genes.
Freshly isolated NK cells were incubated with WF10 (at a chlorite
concentration of 200μM) for 0, 3, or 18h and mRNA was isolated.
The indicated transcripts were quantiﬁed by quantitative RT-PCR.
The number of transcripts of individual genes in each sample was
normalised using the number of transcripts of the house-keeping
genes β-actin and cyclophilin b. The number of transcripts in the
WF10-treated samplewascompared withthenumber oftranscripts
in the control sample using the formula log2 (transcripts WF10
sample/transcripts control sample). Average values and standard
deviation from 5 independent experiments with diﬀerent blood
donors are shown.
receptors on freshly isolated NK cells did not stimulate
cytotoxicity. Also the addition of WF10 did not change this.
However,when we used IL-2-activated NKcells, WF10could
enhance NK cell cytotoxicity mediated by CD16, NKG2D,
NKp30 and 2B4 (Figure 5). This suggests that WF10 acts
independently of one speciﬁc receptor proximal signaling
pathway. Interestingly, WF10 can only costimulate NK cell
cytotoxicity but does not lead to NK cell activation on its
own.
3.4. WF10 Enhances Target Cell Adhesion and Co-Stimulates
the Activation of LFA-1. As WF10 acted independently of
speciﬁc receptor signaling pathways, we tested its eﬀect on
NK cell adhesion to target cells. This adhesion is essential
for NK cell cytotoxicity. It allows the interaction of NK
cell receptors with their ligands on the target cells and is
essentialforthedirectedrelease ofcytotoxicgranules.During
the ﬁrst 90 minutes of conjugate formation between freshly
isolated NK cells and 721.221 target cells WF10 showed
only a minor eﬀect. However, at later time points WF10-
treatmentresultedin anincrease intheamount ofconjugates
(Figure 6(a)). LFA-1 is an important adhesion molecule on
NK cells. The aﬃnity and avidity of LFA-1 for its ligand
ICAM-1 is regulated by inside-out-signals that can derive
from cytokines or the activation of cytotoxicity receptors
[6]. We, therefore, tested the binding activity of LFA-1 using
a ligand-complex-based adhesion assay (LC-AA) [16]. In
this assay ﬂuorescently-labeled ICAM-1 complexes are used
for the staining of cells in a FACS-based analysis. These
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Figure 5: Enhancement of receptor-mediated cytotoxicity of IL-
2-activated NK cells by WF10. IL-2-activated NK cells were tested
in a redirected-lysis assay against murine P815 cells. NK cells
were stimulated using a (a) control antibody, or by antibodies
directed against the activating receptors (b) CD16, (c) NKG2D,
(d) NKp30, or (e) 2B4. Where indicated, WF10 was added to
the assay medium at a ﬁnal chlorite concentration of 200μM.
Average values of triplicates are shownwith the standard deviation.
One representative of three independent experiments with diﬀerent
donors is shown.
complexes will only bind to LFA-1 in its high aﬃnity or high
avidity conformation. Freshly isolated NK cells did not show
binding of ICAM-1 (Figures 6(b) and 6(c)), indicating that
LFA-1 is not activated in resting NK cells. The addition of
WF10didnot changethis,which conﬁrms that WF10cannot
stimulate NK cell activation by its own, but can only costim-
ulate other activation signals. To induce inside-out signaling
we stimulated the NK cells with IL-15, which resulted in
LFA-1 activation (Figure 6(b)). WF10 signiﬁcantly increased
theLFA-1activationafterIL-15incubation(Figures6(b)and
6(c)). These data suggest that WF10 can enhance NK cellJournal of Biomedicine and Biotechnology 5
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Figure 6: WF10 enhances NK cell adhesion. (a) NK cells and
721.221 cells were labeled with a diﬀerent ﬂuorescent dye, washed,
and then incubated together with or without WF10 (200 or
600μM). At the indicated time points the mixed suspension was
ﬁxed with ice-cold 4% PFA and analyzed by FACS. The amount of
NK:721.221 conjugates formedby the cells withoutWF10 was used
as a reference (100%). Average values and the standard deviation
from 3 independent experiments with diﬀerent blood donors are
shown. (b, c) Freshly isolated NK cells were incubated with PE-
conjugated ICAM-1 complex (scICAM-1) with or without WF10
for 3h. Samples were either left unstimulated (b, left panel), or
treated with IL-15 (100 U/ml) (b, right panel). The amount of
bound ICAM-1 complexes wasmeasured by FACS. A representative
experiment is shown in (b). The ICAM-1 binding to control cells
(MFI 44.2 ± 20.4) and IL-15 stimulated cells (MFI 126 ± 60.3)
was used as a reference (100%). (c) Average values and standard
deviations from 5 independent experiments with diﬀerent blood
donors are shown. The ratio of each outcome and its control was
tested against a value of 1 (equality) by two-sided single-sample t-
tests (∗P<. 05).
adhesion to target cells by costimulating inside-out signaling
resulting in higher LFA-1 activity. This would explain the
higher cytotoxic activity of NK cells after WF10-treatment
and suggests that rather than hyperactivating a few NK cells
to kill more frequently, WF10 may increase the number of
NK cells involved in cytotoxicity at a given time, so that
cells that were previously insuﬃciently activated are now
recruited to the killing process by WF10. This would be in
line with our ﬁnding that WF10 can costimulate NK cells,
but not activate them on its own.
4.ConcludingRemarks
WF10 was shown to inhibit the developmentand promotion
of leukemia in animal models [11, 12]. The role of oxidative
species in cancer is complex and has been extensively
studied in the last decades. ROS appear to have a dual
role in tumor development and growth. Oxidative species
contribute to DNA damage, a major step in carcinogenesis
and progression, but they can also act in pro-apoptotic
signaling pathways and, therefore, have antitumor eﬀects
[18]. Due to this dual role, some anticancer strategies are
based on pro-oxidant mechanisms and some on antioxidant
mechanisms [19]. In addition to these direct eﬀects, we
h a v es h o w ni nt h i ss t u d yt h a tW F 1 0c a ns t i m u l a t eN Kc e l l
cytotoxicitythroughpromoting LFA-1-mediatedadhesionto
tumor cells. As NK cells are known to be important eﬀector
cells against hematological malignancies [20], it may be
promising tocombineWF10with otherstrategiesofNKcell-
based immunotherapy against cancer. However, the eﬀects
of WF10 on immune function appears to be modulatory,
rather than either stimulatory or inhibitory. It is, therefore,
expected that a treatment with WF10 could only temporary
enhance NK cell functions, followed by a phase of reduced
NK cell activity. It is unclear if this transient inhibition
of NK cell cytotoxicity, possibly mediated by the down-
regulation of cytotoxicity-related genes such as NKG2D,
DAP12, or perforin, would lead to a gap in immune defense
mechanisms. However, this transient inhibition of NK cell
cytotoxicitymaybeovercomebycombiningtheWF10-based
therapy with stimulatory substances, such as Interleukin-
15, for which a synergistic eﬀect in combination with
WF10 has been shown in our study. Additionally, our data
would suggest that it may be beneﬁcial to administer WF10
in individual boosts rather than maintaining a constant
drug level in order to exploit its inﬂuence on NK cell
activity.
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